Lapses at the New England Journal of Medicine

Journal of the Royal Society of Medicine

Volumn 99, Issue 8, 2006, Pages 380-382

  Smith, Richard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; ROFECOXIB;

CLINICAL TRIAL; DRUG MARKETING; EDITORIAL; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; MEDICAL ETHICS; MEDICAL LITERATURE; MEDICAL RESEARCH; PUBLICATION; THROMBOEMBOLISM;

EID: 33748675501     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.99.8.380     Document Type: Editorial

References (19)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patiente with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
2. Lexchin J, Light DW. Commercial influence and the content of medical journals. BMJ 2006;332:1444-7 [doi:10.1136/bmj.332.7555.1444]
3. Horton R. The dawn of McScience. NY Rev Books 2004;51:7-9
4. Armstrong D. Bitter pill: how the New England Journal missed warning signs on Vioxx. Wall Street Journal 2006 May 15:A1
5. Altman LK. For science's gatekeepers: a credibility gap. New York Times 2006 May 2
6. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005;2:e138
7. James H. The Bostonians. Harmondsworth: Penguin, 2000
8. Angell M. The Truth About Drug Companies: How They Deceive Us and What To Do About It. New York: Random House, 2005
9. Kassirer JP. On The Take: How Medicine's Complicity With Big Business Can Endanger Your Health. New York: Oxford University Press, 2004
10. Gottlieb S. FDA censures NEJM editor. BMJ 2000;320:1562
11. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., 'Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis'. N Engl J Med 2000;343:1520-8.
12. N Engl J Med 2005;353:2813-14
13. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med 2006;354:1193 [http://www.nejm.org]
14. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9
15. FitzGerald GA, Patrono C. Drug therapy: the coxibs, selective inhibitors of cycooxygenase-2. New Engl J Med 2001;345:433-42
16. Anonymous. Correction. N Engl J Med 2006; 355: ?pages? [http://content.nejm.org/cgi/content/short/NEJMx060029]
17. Bresalier RS, Sandier RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
18. Smith R. Peer review: a flawed process at the heart of science and journals. J R Soc Med 2006;99:178-82
19. Smith R, Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials 2006;1:e6 [DOI: 10.1371/journal.pctr.0010006]